(S)-3-((5-nitropyridine-2-yl)amino)propane-1,2-diol

• 分子结构分类: 有机化合物 - 有机1,3-偶极化合物 - 烯丙基型1,3-偶极有机化合物
• 英文名称: (S)-3-((5-nitropyridine-2-yl)amino)propane-1,2-diol
• 英文别名: (2S)-3-[(5-nitropyridin-2-yl)amino]propane-1,2-diol
• 化学式: C₈H₁₁N₃O₄
• 分子量: 213.193
• InChiKey: IYCQNPBENNXHKL-ZETCQYMHSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  15
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  111
• 氢给体数：
  3
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  (S)-3-((5-nitropyridine-2-yl)amino)propane-1,2-diol 在 palladium on activated charcoal 、 氢气 作用下， 以 甲醇 为溶剂， 以100 %的产率得到(S)-3-((5-aminopyridin-2-yl)amino(propane-1,2-diol))
  参考文献：
  名称：

  [EN] BICYCLIC COMPOUNDS
  [FR] COMPOSÉS BICYCLIQUES

  摘要：

  Provided herein are compounds of Formula (I), or pharmaceutically acceptable salts thereof, pharmaceutical compositions that include a compound described herein (including pharmaceutically acceptable salts of a compound described herein) and methods of synthesizing the same. Also provided herein are methods of treating diseases and/or conditions, including hepatitis B vims (HBV) and hepatitis D vims (HDV) infection, with a compound of Formula (I), or a pharmaceutically acceptable salt thereof.

  公开号：

  WO2023205653A1
• 作为产物：
  描述：

  2-氟-5-硝基吡啶 、 (S)-3-氨基-1,2-丙二醇 在 三乙胺 作用下， 以 四氢呋喃 为溶剂， 以61 %的产率得到(S)-3-((5-nitropyridine-2-yl)amino)propane-1,2-diol
  参考文献：
  名称：

  [EN] BICYCLIC COMPOUNDS
  [FR] COMPOSÉS BICYCLIQUES

  摘要：

  Provided herein are compounds of Formula (I), or pharmaceutically acceptable salts thereof, pharmaceutical compositions that include a compound described herein (including pharmaceutically acceptable salts of a compound described herein) and methods of synthesizing the same. Also provided herein are methods of treating diseases and/or conditions, including hepatitis B vims (HBV) and hepatitis D vims (HDV) infection, with a compound of Formula (I), or a pharmaceutically acceptable salt thereof.

  公开号：

  WO2023205653A1

文献信息

• [EN] BICYCLIC COMPOUNDS<br/>[FR] COMPOSÉS BICYCLIQUES
  申请人：[en]ALIGOS THERAPEUTICS, INC.

  公开号：WO2023205653A1

  公开（公告）日：2023-10-26

  Provided herein are compounds of Formula (I), or pharmaceutically acceptable salts thereof, pharmaceutical compositions that include a compound described herein (including pharmaceutically acceptable salts of a compound described herein) and methods of synthesizing the same. Also provided herein are methods of treating diseases and/or conditions, including hepatitis B vims (HBV) and hepatitis D vims (HDV) infection, with a compound of Formula (I), or a pharmaceutically acceptable salt thereof.